1 Semi-solid Dosage Market Overview
1.1 Product Overview and Scope of Semi-solid Dosage
1.2 Semi-solid Dosage Segment by Type
1.2.1 Global Semi-solid Dosage Market Value Comparison by Type (2023-2029)
1.2.2 Ointment
1.2.3 Paste
1.2.4 Plaster
1.2.5 Gel
1.3 Semi-solid Dosage Segment by Application
1.3.1 Global Semi-solid Dosage Market Value by Application: (2023-2029)
1.3.2 Skin
1.3.3 Nasal Cavity
1.3.4 Vaginal Cavity
1.3.5 Rectal Cavity
1.3.6 Other
1.4 Global Semi-solid Dosage Market Size Estimates and Forecasts
1.4.1 Global Semi-solid Dosage Revenue 2018-2029
1.4.2 Global Semi-solid Dosage Sales 2018-2029
1.4.3 Global Semi-solid Dosage Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Semi-solid Dosage Market Competition by Manufacturers
2.1 Global Semi-solid Dosage Sales Market Share by Manufacturers (2018-2023)
2.2 Global Semi-solid Dosage Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Semi-solid Dosage Average Price by Manufacturers (2018-2023)
2.4 Global Semi-solid Dosage Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Semi-solid Dosage, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Semi-solid Dosage, Product Type & Application
2.7 Semi-solid Dosage Market Competitive Situation and Trends
2.7.1 Semi-solid Dosage Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Semi-solid Dosage Players Market Share by Revenue
2.7.3 Global Semi-solid Dosage Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Semi-solid Dosage Retrospective Market Scenario by Region
3.1 Global Semi-solid Dosage Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Semi-solid Dosage Global Semi-solid Dosage Sales by Region: 2018-2029
3.2.1 Global Semi-solid Dosage Sales by Region: 2018-2023
3.2.2 Global Semi-solid Dosage Sales by Region: 2024-2029
3.3 Global Semi-solid Dosage Global Semi-solid Dosage Revenue by Region: 2018-2029
3.3.1 Global Semi-solid Dosage Revenue by Region: 2018-2023
3.3.2 Global Semi-solid Dosage Revenue by Region: 2024-2029
3.4 North America Semi-solid Dosage Market Facts & Figures by Country
3.4.1 North America Semi-solid Dosage Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Semi-solid Dosage Sales by Country (2018-2029)
3.4.3 North America Semi-solid Dosage Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Semi-solid Dosage Market Facts & Figures by Country
3.5.1 Europe Semi-solid Dosage Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Semi-solid Dosage Sales by Country (2018-2029)
3.5.3 Europe Semi-solid Dosage Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Semi-solid Dosage Market Facts & Figures by Country
3.6.1 Asia Pacific Semi-solid Dosage Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Semi-solid Dosage Sales by Country (2018-2029)
3.6.3 Asia Pacific Semi-solid Dosage Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Semi-solid Dosage Market Facts & Figures by Country
3.7.1 Latin America Semi-solid Dosage Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Semi-solid Dosage Sales by Country (2018-2029)
3.7.3 Latin America Semi-solid Dosage Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Semi-solid Dosage Market Facts & Figures by Country
3.8.1 Middle East and Africa Semi-solid Dosage Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Semi-solid Dosage Sales by Country (2018-2029)
3.8.3 Middle East and Africa Semi-solid Dosage Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Semi-solid Dosage Sales by Type (2018-2029)
4.1.1 Global Semi-solid Dosage Sales by Type (2018-2023)
4.1.2 Global Semi-solid Dosage Sales by Type (2024-2029)
4.1.3 Global Semi-solid Dosage Sales Market Share by Type (2018-2029)
4.2 Global Semi-solid Dosage Revenue by Type (2018-2029)
4.2.1 Global Semi-solid Dosage Revenue by Type (2018-2023)
4.2.2 Global Semi-solid Dosage Revenue by Type (2024-2029)
4.2.3 Global Semi-solid Dosage Revenue Market Share by Type (2018-2029)
4.3 Global Semi-solid Dosage Price by Type (2018-2029)
5 Segment by Application
5.1 Global Semi-solid Dosage Sales by Application (2018-2029)
5.1.1 Global Semi-solid Dosage Sales by Application (2018-2023)
5.1.2 Global Semi-solid Dosage Sales by Application (2024-2029)
5.1.3 Global Semi-solid Dosage Sales Market Share by Application (2018-2029)
5.2 Global Semi-solid Dosage Revenue by Application (2018-2029)
5.2.1 Global Semi-solid Dosage Revenue by Application (2018-2023)
5.2.2 Global Semi-solid Dosage Revenue by Application (2024-2029)
5.2.3 Global Semi-solid Dosage Revenue Market Share by Application (2018-2029)
5.3 Global Semi-solid Dosage Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Johnson & Johnson
6.1.1 Johnson & Johnson Corporation Information
6.1.2 Johnson & Johnson Description and Business Overview
6.1.3 Johnson & Johnson Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Johnson & Johnson Semi-solid Dosage Product Portfolio
6.1.5 Johnson & Johnson Recent Developments/Updates
6.2 Merck & Co
6.2.1 Merck & Co Corporation Information
6.2.2 Merck & Co Description and Business Overview
6.2.3 Merck & Co Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Merck & Co Semi-solid Dosage Product Portfolio
6.2.5 Merck & Co Recent Developments/Updates
6.3 Bayer AG
6.3.1 Bayer AG Corporation Information
6.3.2 Bayer AG Description and Business Overview
6.3.3 Bayer AG Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Bayer AG Semi-solid Dosage Product Portfolio
6.3.5 Bayer AG Recent Developments/Updates
6.4 Hisamitsu Pharmaceutical
6.4.1 Hisamitsu Pharmaceutical Corporation Information
6.4.2 Hisamitsu Pharmaceutical Description and Business Overview
6.4.3 Hisamitsu Pharmaceutical Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Hisamitsu Pharmaceutical Semi-solid Dosage Product Portfolio
6.4.5 Hisamitsu Pharmaceutical Recent Developments/Updates
6.5 Glenmark Pharmaceuticals
6.5.1 Glenmark Pharmaceuticals Corporation Information
6.5.2 Glenmark Pharmaceuticals Description and Business Overview
6.5.3 Glenmark Pharmaceuticals Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Glenmark Pharmaceuticals Semi-solid Dosage Product Portfolio
6.5.5 Glenmark Pharmaceuticals Recent Developments/Updates
6.6 Cipla Ltd
6.6.1 Cipla Ltd Corporation Information
6.6.2 Cipla Ltd Description and Business Overview
6.6.3 Cipla Ltd Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Cipla Ltd Semi-solid Dosage Product Portfolio
6.6.5 Cipla Ltd Recent Developments/Updates
6.7 Nestle SA
6.6.1 Nestle SA Corporation Information
6.6.2 Nestle SA Description and Business Overview
6.6.3 Nestle SA Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Nestle SA Semi-solid Dosage Product Portfolio
6.7.5 Nestle SA Recent Developments/Updates
6.8 Novartis AG
6.8.1 Novartis AG Corporation Information
6.8.2 Novartis AG Description and Business Overview
6.8.3 Novartis AG Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Novartis AG Semi-solid Dosage Product Portfolio
6.8.5 Novartis AG Recent Developments/Updates
6.9 GlaxoSmithKline plc
6.9.1 GlaxoSmithKline plc Corporation Information
6.9.2 GlaxoSmithKline plc Description and Business Overview
6.9.3 GlaxoSmithKline plc Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.9.4 GlaxoSmithKline plc Semi-solid Dosage Product Portfolio
6.9.5 GlaxoSmithKline plc Recent Developments/Updates
6.10 Bausch Health Companies
6.10.1 Bausch Health Companies Corporation Information
6.10.2 Bausch Health Companies Description and Business Overview
6.10.3 Bausch Health Companies Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Bausch Health Companies Semi-solid Dosage Product Portfolio
6.10.5 Bausch Health Companies Recent Developments/Updates
6.11 Allergan
6.11.1 Allergan Corporation Information
6.11.2 Allergan Semi-solid Dosage Description and Business Overview
6.11.3 Allergan Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Allergan Semi-solid Dosage Product Portfolio
6.11.5 Allergan Recent Developments/Updates
6.12 Biofrontera
6.12.1 Biofrontera Corporation Information
6.12.2 Biofrontera Semi-solid Dosage Description and Business Overview
6.12.3 Biofrontera Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Biofrontera Semi-solid Dosage Product Portfolio
6.12.5 Biofrontera Recent Developments/Updates
6.13 Crown Laboratories
6.13.1 Crown Laboratories Corporation Information
6.13.2 Crown Laboratories Semi-solid Dosage Description and Business Overview
6.13.3 Crown Laboratories Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Crown Laboratories Semi-solid Dosage Product Portfolio
6.13.5 Crown Laboratories Recent Developments/Updates
6.14 Akorn
6.14.1 Akorn Corporation Information
6.14.2 Akorn Semi-solid Dosage Description and Business Overview
6.14.3 Akorn Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Akorn Semi-solid Dosage Product Portfolio
6.14.5 Akorn Recent Developments/Updates
6.15 Ingenus Pharmaceuticals
6.15.1 Ingenus Pharmaceuticals Corporation Information
6.15.2 Ingenus Pharmaceuticals Semi-solid Dosage Description and Business Overview
6.15.3 Ingenus Pharmaceuticals Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Ingenus Pharmaceuticals Semi-solid Dosage Product Portfolio
6.15.5 Ingenus Pharmaceuticals Recent Developments/Updates
6.16 Sun Pharmaceuticals
6.16.1 Sun Pharmaceuticals Corporation Information
6.16.2 Sun Pharmaceuticals Semi-solid Dosage Description and Business Overview
6.16.3 Sun Pharmaceuticals Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.16.4 Sun Pharmaceuticals Semi-solid Dosage Product Portfolio
6.16.5 Sun Pharmaceuticals Recent Developments/Updates
6.17 Crescita Therapeutics
6.17.1 Crescita Therapeutics Corporation Information
6.17.2 Crescita Therapeutics Semi-solid Dosage Description and Business Overview
6.17.3 Crescita Therapeutics Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.17.4 Crescita Therapeutics Semi-solid Dosage Product Portfolio
6.17.5 Crescita Therapeutics Recent Developments/Updates
6.18 Mylan N.V.
6.18.1 Mylan N.V. Corporation Information
6.18.2 Mylan N.V. Semi-solid Dosage Description and Business Overview
6.18.3 Mylan N.V. Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.18.4 Mylan N.V. Semi-solid Dosage Product Portfolio
6.18.5 Mylan N.V. Recent Developments/Updates
6.19 Encore Dermatology
6.19.1 Encore Dermatology Corporation Information
6.19.2 Encore Dermatology Semi-solid Dosage Description and Business Overview
6.19.3 Encore Dermatology Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.19.4 Encore Dermatology Semi-solid Dosage Product Portfolio
6.19.5 Encore Dermatology Recent Developments/Updates
6.20 LEO Pharma
6.20.1 LEO Pharma Corporation Information
6.20.2 LEO Pharma Semi-solid Dosage Description and Business Overview
6.20.3 LEO Pharma Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.20.4 LEO Pharma Semi-solid Dosage Product Portfolio
6.20.5 LEO Pharma Recent Developments/Updates
6.21 Almirall, S.A
6.21.1 Almirall, S.A Corporation Information
6.21.2 Almirall, S.A Semi-solid Dosage Description and Business Overview
6.21.3 Almirall, S.A Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.21.4 Almirall, S.A Semi-solid Dosage Product Portfolio
6.21.5 Almirall, S.A Recent Developments/Updates
6.22 Aclaris Therapeutics
6.22.1 Aclaris Therapeutics Corporation Information
6.22.2 Aclaris Therapeutics Semi-solid Dosage Description and Business Overview
6.22.3 Aclaris Therapeutics Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.22.4 Aclaris Therapeutics Semi-solid Dosage Product Portfolio
6.22.5 Aclaris Therapeutics Recent Developments/Updates
6.23 Taro Pharmaceutical Industries
6.23.1 Taro Pharmaceutical Industries Corporation Information
6.23.2 Taro Pharmaceutical Industries Semi-solid Dosage Description and Business Overview
6.23.3 Taro Pharmaceutical Industries Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.23.4 Taro Pharmaceutical Industries Semi-solid Dosage Product Portfolio
6.23.5 Taro Pharmaceutical Industries Recent Developments/Updates
6.24 Teligent Pharma
6.24.1 Teligent Pharma Corporation Information
6.24.2 Teligent Pharma Semi-solid Dosage Description and Business Overview
6.24.3 Teligent Pharma Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.24.4 Teligent Pharma Semi-solid Dosage Product Portfolio
6.24.5 Teligent Pharma Recent Developments/Updates
6.25 Perrigo Pharma
6.25.1 Perrigo Pharma Corporation Information
6.25.2 Perrigo Pharma Semi-solid Dosage Description and Business Overview
6.25.3 Perrigo Pharma Semi-solid Dosage Sales, Revenue and Gross Margin (2018-2023)
6.25.4 Perrigo Pharma Semi-solid Dosage Product Portfolio
6.25.5 Perrigo Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Semi-solid Dosage Industry Chain Analysis
7.2 Semi-solid Dosage Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Semi-solid Dosage Production Mode & Process
7.4 Semi-solid Dosage Sales and Marketing
7.4.1 Semi-solid Dosage Sales Channels
7.4.2 Semi-solid Dosage Distributors
7.5 Semi-solid Dosage Customers
8 Semi-solid Dosage Market Dynamics
8.1 Semi-solid Dosage Industry Trends
8.2 Semi-solid Dosage Market Drivers
8.3 Semi-solid Dosage Market Challenges
8.4 Semi-solid Dosage Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Table 1. Global Semi-solid Dosage Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Semi-solid Dosage Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Semi-solid Dosage Market Competitive Situation by Manufacturers in 2022
Table 4. Global Semi-solid Dosage Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Semi-solid Dosage Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Semi-solid Dosage Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Semi-solid Dosage Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Semi-solid Dosage Average Price (USD/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Semi-solid Dosage, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Semi-solid Dosage, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Semi-solid Dosage, Product Type & Application
Table 12. Global Key Manufacturers of Semi-solid Dosage, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Semi-solid Dosage by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Semi-solid Dosage as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Semi-solid Dosage Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Semi-solid Dosage Sales by Region (2018-2023) & (K Units)
Table 18. Global Semi-solid Dosage Sales Market Share by Region (2018-2023)
Table 19. Global Semi-solid Dosage Sales by Region (2024-2029) & (K Units)
Table 20. Global Semi-solid Dosage Sales Market Share by Region (2024-2029)
Table 21. Global Semi-solid Dosage Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Semi-solid Dosage Revenue Market Share by Region (2018-2023)
Table 23. Global Semi-solid Dosage Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Semi-solid Dosage Revenue Market Share by Region (2024-2029)
Table 25. North America Semi-solid Dosage Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Semi-solid Dosage Sales by Country (2018-2023) & (K Units)
Table 27. North America Semi-solid Dosage Sales by Country (2024-2029) & (K Units)
Table 28. North America Semi-solid Dosage Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Semi-solid Dosage Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Semi-solid Dosage Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Semi-solid Dosage Sales by Country (2018-2023) & (K Units)
Table 32. Europe Semi-solid Dosage Sales by Country (2024-2029) & (K Units)
Table 33. Europe Semi-solid Dosage Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Semi-solid Dosage Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Semi-solid Dosage Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Semi-solid Dosage Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Semi-solid Dosage Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Semi-solid Dosage Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Semi-solid Dosage Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Semi-solid Dosage Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Semi-solid Dosage Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Semi-solid Dosage Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Semi-solid Dosage Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Semi-solid Dosage Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Semi-solid Dosage Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Semi-solid Dosage Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Semi-solid Dosage Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Semi-solid Dosage Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Semi-solid Dosage Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Semi-solid Dosage Sales (K Units) by Type (2018-2023)
Table 51. Global Semi-solid Dosage Sales (K Units) by Type (2024-2029)
Table 52. Global Semi-solid Dosage Sales Market Share by Type (2018-2023)
Table 53. Global Semi-solid Dosage Sales Market Share by Type (2024-2029)
Table 54. Global Semi-solid Dosage Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Semi-solid Dosage Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Semi-solid Dosage Revenue Market Share by Type (2018-2023)
Table 57. Global Semi-solid Dosage Revenue Market Share by Type (2024-2029)
Table 58. Global Semi-solid Dosage Price (USD/Unit) by Type (2018-2023)
Table 59. Global Semi-solid Dosage Price (USD/Unit) by Type (2024-2029)
Table 60. Global Semi-solid Dosage Sales (K Units) by Application (2018-2023)
Table 61. Global Semi-solid Dosage Sales (K Units) by Application (2024-2029)
Table 62. Global Semi-solid Dosage Sales Market Share by Application (2018-2023)
Table 63. Global Semi-solid Dosage Sales Market Share by Application (2024-2029)
Table 64. Global Semi-solid Dosage Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Semi-solid Dosage Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Semi-solid Dosage Revenue Market Share by Application (2018-2023)
Table 67. Global Semi-solid Dosage Revenue Market Share by Application (2024-2029)
Table 68. Global Semi-solid Dosage Price (USD/Unit) by Application (2018-2023)
Table 69. Global Semi-solid Dosage Price (USD/Unit) by Application (2024-2029)
Table 70. Johnson & Johnson Corporation Information
Table 71. Johnson & Johnson Description and Business Overview
Table 72. Johnson & Johnson Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 73. Johnson & Johnson Semi-solid Dosage Product
Table 74. Johnson & Johnson Recent Developments/Updates
Table 75. Merck & Co Corporation Information
Table 76. Merck & Co Description and Business Overview
Table 77. Merck & Co Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 78. Merck & Co Semi-solid Dosage Product
Table 79. Merck & Co Recent Developments/Updates
Table 80. Bayer AG Corporation Information
Table 81. Bayer AG Description and Business Overview
Table 82. Bayer AG Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 83. Bayer AG Semi-solid Dosage Product
Table 84. Bayer AG Recent Developments/Updates
Table 85. Hisamitsu Pharmaceutical Corporation Information
Table 86. Hisamitsu Pharmaceutical Description and Business Overview
Table 87. Hisamitsu Pharmaceutical Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 88. Hisamitsu Pharmaceutical Semi-solid Dosage Product
Table 89. Hisamitsu Pharmaceutical Recent Developments/Updates
Table 90. Glenmark Pharmaceuticals Corporation Information
Table 91. Glenmark Pharmaceuticals Description and Business Overview
Table 92. Glenmark Pharmaceuticals Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 93. Glenmark Pharmaceuticals Semi-solid Dosage Product
Table 94. Glenmark Pharmaceuticals Recent Developments/Updates
Table 95. Cipla Ltd Corporation Information
Table 96. Cipla Ltd Description and Business Overview
Table 97. Cipla Ltd Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 98. Cipla Ltd Semi-solid Dosage Product
Table 99. Cipla Ltd Recent Developments/Updates
Table 100. Nestle SA Corporation Information
Table 101. Nestle SA Description and Business Overview
Table 102. Nestle SA Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 103. Nestle SA Semi-solid Dosage Product
Table 104. Nestle SA Recent Developments/Updates
Table 105. Novartis AG Corporation Information
Table 106. Novartis AG Description and Business Overview
Table 107. Novartis AG Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 108. Novartis AG Semi-solid Dosage Product
Table 109. Novartis AG Recent Developments/Updates
Table 110. GlaxoSmithKline plc Corporation Information
Table 111. GlaxoSmithKline plc Description and Business Overview
Table 112. GlaxoSmithKline plc Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 113. GlaxoSmithKline plc Semi-solid Dosage Product
Table 114. GlaxoSmithKline plc Recent Developments/Updates
Table 115. Bausch Health Companies Corporation Information
Table 116. Bausch Health Companies Description and Business Overview
Table 117. Bausch Health Companies Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 118. Bausch Health Companies Semi-solid Dosage Product
Table 119. Bausch Health Companies Recent Developments/Updates
Table 120. Allergan Corporation Information
Table 121. Allergan Description and Business Overview
Table 122. Allergan Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 123. Allergan Semi-solid Dosage Product
Table 124. Allergan Recent Developments/Updates
Table 125. Biofrontera Corporation Information
Table 126. Biofrontera Description and Business Overview
Table 127. Biofrontera Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 128. Biofrontera Semi-solid Dosage Product
Table 129. Biofrontera Recent Developments/Updates
Table 130. Crown Laboratories Corporation Information
Table 131. Crown Laboratories Description and Business Overview
Table 132. Crown Laboratories Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 133. Crown Laboratories Semi-solid Dosage Product
Table 134. Crown Laboratories Recent Developments/Updates
Table 135. Akorn Corporation Information
Table 136. Akorn Description and Business Overview
Table 137. Akorn Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 138. Akorn Semi-solid Dosage Product
Table 139. Akorn Recent Developments/Updates
Table 140. Ingenus Pharmaceuticals Corporation Information
Table 141. Ingenus Pharmaceuticals Description and Business Overview
Table 142. Ingenus Pharmaceuticals Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 143. Ingenus Pharmaceuticals Semi-solid Dosage Product
Table 144. Ingenus Pharmaceuticals Recent Developments/Updates
Table 145. Sun Pharmaceuticals Corporation Information
Table 146. Sun Pharmaceuticals Description and Business Overview
Table 147. Sun Pharmaceuticals Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 148. Sun Pharmaceuticals Semi-solid Dosage Product
Table 149. Sun Pharmaceuticals Recent Developments/Updates
Table 150. Crescita Therapeutics Corporation Information
Table 151. Crescita Therapeutics Description and Business Overview
Table 152. Crescita Therapeutics Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 153. Crescita Therapeutics Semi-solid Dosage Product
Table 154. Crescita Therapeutics Recent Developments/Updates
Table 155. Mylan N.V. Corporation Information
Table 156. Mylan N.V. Description and Business Overview
Table 157. Mylan N.V. Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 158. Mylan N.V. Semi-solid Dosage Product
Table 159. Mylan N.V. Recent Developments/Updates
Table 160. Encore Dermatology Corporation Information
Table 161. Encore Dermatology Description and Business Overview
Table 162. Encore Dermatology Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 163. Encore Dermatology Semi-solid Dosage Product
Table 164. Encore Dermatology Recent Developments/Updates
Table 165. LEO Pharma Corporation Information
Table 166. LEO Pharma Description and Business Overview
Table 167. LEO Pharma Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 168. LEO Pharma Semi-solid Dosage Product
Table 169. LEO Pharma Recent Developments/Updates
Table 170. Almirall, S.A Corporation Information
Table 171. Almirall, S.A Description and Business Overview
Table 172. Almirall, S.A Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 173. Almirall, S.A Semi-solid Dosage Product
Table 174. Almirall, S.A Recent Developments/Updates
Table 175. Aclaris Therapeutics Corporation Information
Table 176. Aclaris Therapeutics Description and Business Overview
Table 177. Aclaris Therapeutics Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 178. Aclaris Therapeutics Semi-solid Dosage Product
Table 179. Aclaris Therapeutics Recent Developments/Updates
Table 180. Taro Pharmaceutical Industries Corporation Information
Table 181. Taro Pharmaceutical Industries Description and Business Overview
Table 182. Taro Pharmaceutical Industries Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 183. Taro Pharmaceutical Industries Semi-solid Dosage Product
Table 184. Taro Pharmaceutical Industries Recent Developments/Updates
Table 185. Teligent Pharma Corporation Information
Table 186. Teligent Pharma Description and Business Overview
Table 187. Teligent Pharma Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 188. Teligent Pharma Semi-solid Dosage Product
Table 189. Teligent Pharma Recent Developments/Updates
Table 190. Perrigo Pharma Corporation Information
Table 191. Perrigo Pharma Description and Business Overview
Table 192. Perrigo Pharma Semi-solid Dosage Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2018-2023)
Table 193. Perrigo Pharma Semi-solid Dosage Product
Table 194. Perrigo Pharma Recent Developments/Updates
Table 195. Key Raw Materials Lists
Table 196. Raw Materials Key Suppliers Lists
Table 197. Semi-solid Dosage Distributors List
Table 198. Semi-solid Dosage Customers List
Table 199. Semi-solid Dosage Market Trends
Table 200. Semi-solid Dosage Market Drivers
Table 201. Semi-solid Dosage Market Challenges
Table 202. Semi-solid Dosage Market Restraints
Table 203. Research Programs/Design for This Report
Table 204. Key Data Information from Secondary Sources
Table 205. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Semi-solid Dosage
Figure 2. Global Semi-solid Dosage Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Semi-solid Dosage Market Share by Type in 2022 & 2029
Figure 4. Ointment Product Picture
Figure 5. Paste Product Picture
Figure 6. Plaster Product Picture
Figure 7. Gel Product Picture
Figure 8. Global Semi-solid Dosage Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 9. Global Semi-solid Dosage Market Share by Application in 2022 & 2029
Figure 10. Skin
Figure 11. Nasal Cavity
Figure 12. Vaginal Cavity
Figure 13. Rectal Cavity
Figure 14. Other
Figure 15. Global Semi-solid Dosage Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Semi-solid Dosage Market Size (2018-2029) & (US$ Million)
Figure 17. Global Semi-solid Dosage Sales (2018-2029) & (K Units)
Figure 18. Global Semi-solid Dosage Average Price (USD/Unit) & (2018-2029)
Figure 19. Semi-solid Dosage Report Years Considered
Figure 20. Semi-solid Dosage Sales Share by Manufacturers in 2022
Figure 21. Global Semi-solid Dosage Revenue Share by Manufacturers in 2022
Figure 22. The Global 5 and 10 Largest Semi-solid Dosage Players: Market Share by Revenue in 2022
Figure 23. Semi-solid Dosage Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 24. Global Semi-solid Dosage Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 25. North America Semi-solid Dosage Sales Market Share by Country (2018-2029)
Figure 26. North America Semi-solid Dosage Revenue Market Share by Country (2018-2029)
Figure 27. United States Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 28. Canada Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 29. Europe Semi-solid Dosage Sales Market Share by Country (2018-2029)
Figure 30. Europe Semi-solid Dosage Revenue Market Share by Country (2018-2029)
Figure 31. Germany Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 32. France Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 33. U.K. Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. Italy Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. Russia Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Asia Pacific Semi-solid Dosage Sales Market Share by Region (2018-2029)
Figure 37. Asia Pacific Semi-solid Dosage Revenue Market Share by Region (2018-2029)
Figure 38. China Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 39. Japan Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 40. South Korea Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. India Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. Australia Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. China Taiwan Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Indonesia Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. Thailand Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Malaysia Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Latin America Semi-solid Dosage Sales Market Share by Country (2018-2029)
Figure 48. Latin America Semi-solid Dosage Revenue Market Share by Country (2018-2029)
Figure 49. Mexico Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 50. Brazil Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 51. Argentina Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Middle East & Africa Semi-solid Dosage Sales Market Share by Country (2018-2029)
Figure 53. Middle East & Africa Semi-solid Dosage Revenue Market Share by Country (2018-2029)
Figure 54. Turkey Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 55. Saudi Arabia Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 56. UAE Semi-solid Dosage Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 57. Global Sales Market Share of Semi-solid Dosage by Type (2018-2029)
Figure 58. Global Revenue Market Share of Semi-solid Dosage by Type (2018-2029)
Figure 59. Global Semi-solid Dosage Price (USD/Unit) by Type (2018-2029)
Figure 60. Global Sales Market Share of Semi-solid Dosage by Application (2018-2029)
Figure 61. Global Revenue Market Share of Semi-solid Dosage by Application (2018-2029)
Figure 62. Global Semi-solid Dosage Price (USD/Unit) by Application (2018-2029)
Figure 63. Semi-solid Dosage Value Chain
Figure 64. Semi-solid Dosage Production Process
Figure 65. Channels of Distribution (Direct Vs Distribution)
Figure 66. Distributors Profiles
Figure 67. Bottom-up and Top-down Approaches for This Report
Figure 68. Data Triangulation
Figure 69. Key Executives Interviewed
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/